As the pandemic transitioned into an endemic phase, the profit-driven failures continued. The debate over boosters highlighted the disconnect between scientific need and corporate strategy. While vulnerable populations certainly needed boosters, the aggressive push for broad booster campaigns in wealthy nations—even before the Global South had access to first doses—was heavily influenced by corporate revenue projections.
Internal documents and investor calls revealed that pharmaceutical companies viewed boosters as a long-term revenue stream, essentially creating a subscription model for immunity. This drove policy in the West. While the WHO pleaded for a moratorium on boosters to free up supply for poorer nations, rich countries, encouraged by the pharmaceutical narrative, plowed ahead.
This wasn’t just ethically questionable; scientifically, it was debated. Some immunologists argued that targeting specific variants with boosters was necessary, while others argued that the focus should be on cellular immunity and preventing severe disease globally. But the voice of the pharmaceutical industry, amplified by billions in marketing and lobbying, drowned out the nuanced scientific debate. The result was a flood of booster doses in the West, often going into the arms of low-risk individuals, while high-risk healthcare workers in the Global South remained unvaccinated.
The Long-Term Consequences: Preparing for the Next Pandemic
The biggest tragedy of this mistake is that it sets a dangerous precedent for the next pandemic. Big Pharma has now proven that it can profit spectacularly from a global crisis while facing minimal consequences for inequitable distribution. They have effectively written the playbook for future pandemics: get public funding for R&D, secure exclusive patents, sign high-value contracts with wealthy nations, block technology transfer, and donate a token amount to charity for good PR.
If we leave the next pandemic response to the same actors, we can expect the same result: protectionism, hoarding, and a prolonged economic crisis. The current international legal framework, heavily influenced by industry lobbyists, protects pharmaceutical monopolies even during emergencies.
We need a radical paradigm shift. We need to treat essential medicines and vaccines as global public goods, not private commodities. This means:
- Automatic IP Waivers: When the WHO declares a Public Health Emergency of International Concern (PHEIC), patent protections on relevant medical countermeasures should be automatically suspended.
- Public Manufacturing: Governments must invest in publicly owned manufacturing capacity that can be pivoted during crises without the need for private sector permission.
- Price Controls: If public money funds the R&D, the public should set the price.
- Technology Transfer: The WHO’s C-TAP initiative must be strengthened and made mandatory for UN member states receiving public health funding.
The Myth of Innovation vs. The Reality of Greed
A common defense of the pharmaceutical industry is the “innovation argument”—that without the promise of massive profits, these vaccines would not exist. This is a fallacy that ignores the history of the COVID-19 vaccines. The risky early-stage research was funded by governments. The clinical trials were funded by governments. The advance purchase agreements reduced the financial risk to near zero.
Moderna, a company that had never brought a product to market, received nearly a billion dollars in US government funding for its vaccine development. Yet, it refused to share its technology or lower prices for low-income nations. The innovation was socialized, but the profit was privatized.
Furthermore, the industry claims that they worked at “breakneck speed” out of a sense of duty. While the scientists working in the labs undoubtedly did, the corporate leadership acted in standard corporate fashion. They maximized leverage. They bullied governments. They lobbied against their competitors (as seen in the proxy wars between adenovirus vector makers and mRNA makers). Putting these warring fiefdoms in charge of a cooperative global effort was like putting rival pirate captains in charge of a rescue mission. They spent as much time fighting each other and protecting their loot as they did fighting the virus.
Conclusion
The global response to COVID-19 was a tale of two worlds. One world had the wealth to buy tickets to safety, purchasing their way to the front of the line from the monopoly holders. The other world was left behind, waiting for charity, battling variants, and burying their dead. This divide was not inevitable. It was engineered by a system that puts the property rights of corporations above the human rights of populations.
Putting Big Pharma in charge of the global vaccine rollout was a mistake because it accepted a false premise: that the market can solve a crisis that the market itself helped create. The pharmaceutical industry is designed to sell products, not to solve problems. It excels at maximizing revenue, not at maximizing health outcomes. In a crisis, we needed a general leading the charge, but we hired a merchant.
As we look to the future, we must remember the lessons of this failure. We must recognize that health is a human right, not a privilege to be auctioned to the highest bidder. We must build institutions that prioritize the collective good over the corporate bottom line. The next pathogen will not wait for a shareholder meeting to conclude. It will not respect patents or profit margins. If we want to survive the next pandemic, we must take the keys away from Big Pharma and put them back in the hands of the global public. The mistake of 2020 cannot be repeated in 2030. The cost is simply too high.
Disclaimer: The content on this blog is for informational purposes only.  Author’s opinions are personal and not endorsed. Efforts are made to provide accurate information   but completeness, accuracy, or reliability are not guaranteed. Author is not liable for any loss or damage resulting from the use of this blog. It is recommended to use information on this blog at your own terms.
